'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Acne Vulgaris to Dermatology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Acne Vulgaris to Dermatology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Acne Vulgaris Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Acne Vulgaris 29
Jun 29, 2016: BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results for BPX-01 in Patients with Acne-Causing Bacteria 29
May 11, 2016: Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting 29
May 10, 2016: Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris 30
May 09, 2016: Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101 31
Apr 25, 2016: BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for Acne 32
Clinical Trial Profile Snapshots 33
Appendix 354
Abbreviations 354
Definitions 354
Research Methodology 355
Secondary Research 355
About GlobalData 356
Contact Us 356
Disclaimer 356
Source 357
List of Tables
Acne Vulgaris Therapeutics, Global, Clinical Trials by Region, 2016* 6
Acne Vulgaris Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Acne Vulgaris Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Acne Vulgaris Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Acne Vulgaris Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Acne Vulgaris Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Acne Vulgaris Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Acne Vulgaris to Dermatology Clinical Trials, G7 Countries (%), 2016* 14
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Acne Vulgaris to Dermatology Clinical Trials, E7 Countries (%), 2016* 17
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Acne Vulgaris Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Acne Vulgaris Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Acne Vulgaris Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Acne Vulgaris Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Acne Vulgaris Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Acne Vulgaris Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Acne Vulgaris Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Acne Vulgaris Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
List of Figures
Acne Vulgaris Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Acne Vulgaris Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Acne Vulgaris Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Acne Vulgaris Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Acne Vulgaris Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Acne Vulgaris Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Acne Vulgaris Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Acne Vulgaris to Dermatology Clinical Trials, G7 Countries (%), 2016* 14
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Acne Vulgaris to Dermatology Clinical Trials, E7 Countries (%), 2016* 17
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Acne Vulgaris Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Acne Vulgaris Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Acne Vulgaris Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Acne Vulgaris Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Acne Vulgaris Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Acne Vulgaris Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Acne Vulgaris Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Acne Vulgaris Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 355